# Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Source: https://onco.cc/key-papers/paper-epcoritamab-dlbcl-blood-2025/  
OnCo record `paper-epcoritamab-dlbcl-blood-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Phase 2 or 3 results paper on Epcoritamab in Diffuse large B-cell lymphoma, in Blood (2025), one of the most cited Europe PMC records with Epcoritamab in its title.

## Summary

Abstract: Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes (complete response [CR] rates with standard salvage therapy gemcitabine plus oxaliplatin [GemOx], ∼30%; median overall survival [OS], 10 to 13 months). Patients with refractory disease fare worse (CR rate with salvage therapy, 7%; median OS, 6 months). Epcoritamab, a CD3×CD20 bispecific antibody approved for R/R DLBCL after ≥2 therapy lines, has shown promising safety and efficacy in various combinations. We report results from the phase 1b/2 EPCORE NHL-2 trial evaluating epcoritamab plus GemOx in autologous stem cell transplant (ASCT)-ineligible R/R DLBCL. Patients received 48 mg subcutaneous epcoritamab after 2 step-up doses until progression or unacceptable toxicity; GemOx was given once every 2 weeks for 8 doses. The primary end point was overall response rate (ORR). at 15 December 2023, 103 patients were enrolled (median follow-up, 13.2 months; median age, 72 years). Patients had challenging-to-treat disease: ≥2 prior therapy lines, 62%; prior chimeric antigen receptor T-cell therapy, 28%; primary refractory disease, 52%; refractory to last therapy, 70%. ORR and CR rate were 85% and 61%, respectively. Median duration of CR and OS were 23.6 and 21.6 months, respectively. Common treatment-emergent adverse events were cytopenias and cytokine release syndrome (CRS). CRS events had predictable timing, were primarily low grade (52% overall, 1% grade 3), and resolved without leading to discontinuation. Epcoritamab plus GemOx yielded deep, durable responses and favorable long-term outcomes in ASCT-ineligible R/R DLBCL. This trial was registered at www.clinicaltrials.gov as #NCT04663347.

Indexed on Europe PMC as PubMed record 39792928 (DOI 10.1182/blood.2024026830). Its title names Epcoritamab and its text names Diffuse large B-cell lymphoma; PubMed types it as a clinical trial report (Clinical Trial, Phase II, research-article, Multicenter Study, Clinical Trial, Phase I). It was matched automatically to the idea "ctDNA-guided escalation and de-escalation in frontline DLBCL" and no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Blood
- Year: 2025
- DOI: 10.1182/blood.2024026830
- Authors: Brody JD, Jørgensen J, Belada D, et al.
- What it means: One of the most cited trial reports Europe PMC returns for Epcoritamab in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Caveats: Matched by Epcoritamab in the title and Diffuse large B-cell lymphoma in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; Chosen as a phase 2 or 3 report by the record's publication type or its own wording, not by reading the paper.

## Sources

- Blood 2025: https://doi.org/10.1182/blood.2024026830
- PubMed: https://pubmed.ncbi.nlm.nih.gov/39792928/
- Europe PMC: https://europepmc.org/article/MED/39792928
- ClinicalTrials.gov NCT04663347: https://clinicaltrials.gov/study/NCT04663347

## Connected records

- trials: [Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)](https://onco.cc/trials/nct04663347/)
- journals: [Blood](https://onco.cc/journals/blood/)
- ideas: [ctDNA-guided escalation and de-escalation in frontline DLBCL](https://onco.cc/ideas/idea-ctdna-guided-dlbcl-frontline/)

---
JSON: https://onco.cc/api/v1/entities/paper-epcoritamab-dlbcl-blood-2025.json